This transgene contains a calcium-sensing molecule, GCaMP2, under the transcriptional control of a minimally active mouse alpha myosin heavy chain promoter fused to seven copies of the tetracycline-responsive promoter element (tetO). GCaMP2 consists of circularly permutated eGFP with the molecule interrupted at residue 145 and a 13-residue peptide of myosin light chain kinase (M13) and calmodulin (CaM), placed at the new N and C termini, respectively. An RSET polyHis peptide was introduced N-terminal to the original methionine in GCaMP1. Mutations resulting in increased brightness (D180Y and V93I), thermal stability (V163A, and S175G) and to prevent GFP dimerization (A206K) were introduced. GCaMP2 is 200 times brighter than GCaMP1. Three GATA sites and two thyroid-like response elements are ablated in Myh6 to make the promoter minimally active. When bred with transgenic mice expressing a tetracycline transactivator or reverse transactivator protein, cardiac-specific expression of GCaMP2 can be controlled by withdrawal or administration of a tetracycline analog. (J:107637)
查看原文 参与反馈

基础信息

模型ID
品系来源
等位基因类型
突变
遗传方式
基因表达
相关疾病
参考文献
(C57BL/6 x DBA/2)F2
--
Insertion
--
2
--
2

表型特征

标签摘要:
hm: 纯合子
ht: 杂合子
cn: 条件基因型
cx: 复合型:涉及多基因组
tg: 转基因
ot: 其他:半合子、不确定...
(F): 雌性
(M): 雄性
观察到的表型
N: 正常表型
(#): 上标括号内为相关疾病数量
模型表型:
显示/隐藏列
表型

文献报道

标题
PMID
期刊
年代
IF
暂无数据
Wechat
Comparison
Al agent
Tutorials
Back to top